Investigational drug · Phase 3
Duvakitug
Also called: SAR447189, TEV-48574 A, TEV-48574 B
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ulcerative Colitis, Crohn's Disease, Hidradenitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
8
Any phase or sponsor naming "Duvakitug"
First trial start
2023
Jan 11, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Duvakitug", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ulcerative Colitis
- Crohn's Disease
- Hidradenitis
- Crohn Disease
- Colitis, Ulcerative
Approved drugs for the same conditions: Crohn's disease · Ulcerative colitis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Duvakitug" as an intervention, largest first.
- An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07184996 · 980 participants (planned) · Start Oct 8, 2025 · Primary completion May 9, 2028
Drug: Duvakitug; Placebo · For: Ulcerative Colitis
Sites: Peoria, Arizona; Scottsdale, Arizona; Tucson, Arizona · 240 sites in all
- An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07184931 · 980 participants (planned) · Start Oct 1, 2025 · Primary completion May 14, 2029
Drug: Duvakitug; Placebo · For: Crohn's Disease
Sites: Peoria, Arizona; Scottsdale, Arizona; Tucson, Arizona · 461 sites in all
- A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07185009 · 751 participants (planned) · Start Jan 16, 2026 · Primary completion Sep 21, 2028
Drug: Duvakitug; Placebo · For: Ulcerative Colitis
Sites: Tucson, Arizona; Coronado, California; Murrieta, California · 171 sites in all
- A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07184944 · 751 participants (planned) · Start Jan 22, 2026 · Primary completion Aug 13, 2029
Drug: Duvakitug; Placebo · For: Crohn's Disease
Sites: Colorado Springs, Colorado; Kissimmee, Florida; Miami, Florida · 109 sites in all
- A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's DiseasePivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT05499130 · 290 participants · Start Sep 30, 2022 · Primary completion Nov 12, 2024
Drug: TEV-48574; Placebo · For: Crohn Disease; Colitis, Ulcerative
Sites: Sun City, Arizona; San Diego, California; Kissimmee, Florida · 164 sites in all
- A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's DiseasePivotal-lookingActive, not recruiting
Teva Branded Pharmaceutical Products R&D LLCTeva (TEVA)
NCT05668013 · 247 participants · Start Jan 11, 2023 · Primary completion Jan 5, 2026
Drug: TEV-48574 Dose Regimen A; TEV-48574 Dose Regiment B · For: Crohn Disease; Colitis, Ulcerative
Sites: San Diego, California; Kissimmee, Florida; Orlando, Florida · 93 sites in all
- A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07812116 · 156 participants (planned) · Start Oct 19, 2026 · Primary completion Jun 16, 2028
Drug: Duvakitug; Placebo · For: Hidradenitis
Sites: Birmingham, Alabama; Miami, Florida; Peterborough, Canada · 4 sites in all
- An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 SubstratesNot yet recruiting
SanofiSanofi (SNY)
NCT07923383 · 25 participants (planned) · Start Nov 3, 2026 · Primary completion Aug 8, 2028
Drug: Duvakitug · For: Ulcerative Colitis; Crohn's Disease
Newest research
PubMed records naming it or its code names, newest first.
- TL1A-DR3 Signaling in Inflammatory Bowel Disease: From Pathogenesis to Therapeutic Targeting.
Tsuruta K, Yoshioka S, Takedatsu H · Kurume Med J 2026
- Targeting the TL1A pathway in inflammatory bowel disease: mechanistic insights and emerging therapeutic pipeline.
Quraishi MN, Jairath V, Al-Bawardy B · Inflamm Bowel Dis 2026
- Relieving IBD with duvakitug.
Ray K · Nat Rev Gastroenterol Hepatol 2026
- Tumor necrosis factor-like cytokine 1ߙA antagonists for inflammatory bowel disease: A systematic review and meta-analysis.
Paudel MS, Sharma V, Bhattarai K, et al. · Indian J Gastroenterol 2026
- TL1A inhibitors in inflammatory bowel disease: A systematic review of phase 2 clinical trials.
Choi JG, Gong EJ, Bang CS, et al. · Saudi J Gastroenterol 2026
- Novel Agents on the Therapeutic Horizon For Paediatric Inflammatory Bowel Diseases: An Analysis of Clinical Trials Registries.
Gupte D, Suthar NR, MacDonald JK, et al. · Paediatr Drugs 2026
Also in development for Ulcerative Colitis
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- FilgotinibGS-6034, GLPG0634Phase 36 trials
Alfasigma S.p.A. · Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA)
- ABX464ObefazimodPhase 35 trials
Abivax S.A. · Ulcerative Colitis, Moderately to Severely Active Crohn Disease
- brivekimigSAR442970Phase 25 trials
Sanofi · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus
- MORF-057zotemtegrast, LY4268989Phase 24 trials
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC)
- ABBV-701Phase 22 trials
AbbVie · Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.